Treatment of Pompe Disease
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pompe Disease Treatment</th>
</tr>
<tr>
<td class="label">Aid</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Canes</td>
<td>Early ambulatory weakness</td>
</tr>
<tr>
<td class="label">Walkers</td>
<td>Moderate weakness</td>
</tr>
<tr>
<td class="label">Wheelchairs</td>
<td>Long-distance mobility, fatigue</td>
</tr>
<tr>
<td class="label">Power wheelchair</td>
<td>Severe weakness</td>
</tr>
<tr>
<td class="label">Home modifications</td>
<td>Bathroom, stairs, kitchen</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Urinary glucose tetrasaccharide (Glc4)</td>
<td>Disease burden, treatment response</td>
</tr>
<tr>
<td class="label">Creatine kinase (CK)</td>
<td>Muscle damage</td>
</tr>
<tr>
<td class="label">GAA activity</td>
<td>Diagnosis, treatment monitoring</td>
</tr>
<tr>
<td class="label">Anti-GAA antibodies</td>
<td>Treatment response, immunogenicity</td>
</tr>
<tr>
<td class="label">Neurofilament light chain (NfL)</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ERT + gene therapy</td>
<td>Different mechanisms, enhanced effect</td>
</tr>
<tr>
<td class="label">ERT + chaperone</td>
<td>Improved enzyme stability</td>
</tr>
<tr>
<td class="label">Gene therapy + chaperone</td>
<td>Enhanced folding</td>
</tr>
<tr>
<td class="label">Multiple modalities</td>
<td>Maximum glycogen clearance</td>
</tr>
</table>
Overview
Pompe disease (Glycogen Storage Disease Type II, GSD II) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA)[@kishnani2015]. This deficiency leads to accumulation of glycogen primarily in skeletal and cardiac muscle, resulting in progressive muscle weakness, respiratory insufficiency, and in infantile-onset cases, severe cardiac involvement. The disease exists on a spectrum from classic infantile-onset Pompe disease (IOPD) with rapid progression to late-onset Pompe disease (LOPD) with slower but still progressive weakness.
Treatment of Pompe disease has been revolutionized by enzyme replacement therapy (ERT), which has dramatically improved outcomes, particularly in infantile-onset disease. However, significant challenges remain, including incomplete efficacy, immunogenicity of recombinant enzymes, and the need for multidisciplinary care. This article provides a comprehensive overview of current and emerging therapeutic approaches for Pompe disease.
Enzyme Replacement Therapy
Alglucosidase Alfa (Myozyme/Lumizyme)
Alglucosidase alfa (marketed as Myozyme in Europe and Lumizyme in the United States) was the first FDA-approved enzyme replacement therapy for Pompe disease and remains a cornerstone of treatment[@van2010].
Characteristics:
- Recombinant human acid alpha-glucosidase (rhGAA) produced in Chinese hamster ovary (CHO) cells
- Administered via intravenous infusion every 2 weeks
- Standard dose: 20 mg/kg body weight
- Infusion duration: 2-4 hours
Clinical outcomes in IOPD:
- Significantly improved survival compared to historical controls
- Improved ventilator-free survival
- Reduced need for cardiac surgery
- Improved motor development
- Best outcomes when initiated before 6 months of age[@james2019]
Clinical outcomes in LOPD:
- Stabilization or slowing of disease progression
- Improved motor function in some patients
- Stabilization of respiratory function
- Benefits continue with long-term treatment[@schoser2018]
Limitations:
- Does not cross the blood-brain barrier significantly
- Limited efficacy in some patients
- Immunogenicity: development of neutralizing antibodies
- Infusion-associated reactions (IARs) in ~35% of patients
Avalglucosidase Alfa (Pombilta)
Avalglucosidase alfa (Pombilta) is a next-generation ERT designed with improved targeting to muscle tissue[@ansong2021].
Design improvements:
- Engineered rhGAA with increased mannose-6-phosphate (M6P) content
- Enhanced uptake via M6P receptors on target cells
- Improved lysosomal delivery and glycogen clearance
Clinical data:
- FDA-approved in 2021 for both IOPD and LOPD
- Comparable efficacy to alglucosidase alfa with potentially improved tissue targeting
- Same dosing regimen (20 mg/kg every 2 weeks)
- Approved for patients 1 year and older
Safety profile:
- Generally well-tolerated
- Similar IAR profile to alglucosidase alfa
- Lower rates of antibody formation in some studies
Cipaglucosidase Alfa (AT-GAA)
Cipaglucosidase alfa (AT-GAA) represents a novel ERT formulation designed for enhanced cellular uptake and is administered with the pharmacological chaperone miglustat[@byrne2020].
Dual approach:
- AT-GAA: Enhanced rhGAA with optimized glycosylation
- Miglustat (AT222): Pharmacological chaperone to stabilize enzyme
- Co-administration improves enzyme stability and activity
Clinical trials:
- Phase 1/2 studies showed promising results in LOPD
- Phase 3 PROPEL trial demonstrated efficacy
- FDA approval anticipated
Advantages:
- Improved tissue targeting
- Enhanced enzyme activity
- Potential for better clinical outcomes
Supportive Care
Respiratory Management
Respiratory insufficiency is a major cause of morbidity in Pompe disease and requires proactive management[@stephen2020]:
Monitoring:
- Pulmonary function tests every 6-12 months
- Vital capacity in sitting and supine positions
- Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)
- Overnight oximetry and sleep studies for nocturnal hypoventilation
- Blood gas analysis
Interventions:
- Non-invasive ventilation (BiPAP/CPAP): For nocturnal hypoventilation or daytime hypercapnia
- Mechanical insufflation-exsufflation: For cough assistance
- Secretion clearance techniques: Mechanical percussion, chest physiotherapy
- Mechanical ventilation: For advanced respiratory failure
- Treatment of respiratory infections: Prompt antibiotics, aggressive clearance
Cardiac Management
Cardiac involvement is most prominent in IOPD but can also occur in LOPD[@lorenzoni2020]:
Monitoring:
- Echocardiography annually
- ECG and Holter monitoring
- BNP/NT-proBNP for heart failure
Management:
- Treatment of hypertrophic cardiomyopathy (beta-blockers, ACE inhibitors)
- Arrhythmia management (antiarrhythmics, pacemakers)
- Heart failure treatment per standard protocols
- In severe cases, cardiac transplantation (rare)
Rehabilitation
Physical therapy is essential for maintaining function in Pompe disease[@leonard2016]:
Physical therapy:
- Gentle, low-impact exercise (swimming, walking)
- Stretching to prevent contractures
- Aerobic conditioning within safe limits
- Balance and gait training
Occupational therapy:
- Energy conservation techniques
- Adaptive equipment for ADLs
- Home modifications
Speech therapy:
- Evaluation and treatment of dysphagia
- Communication aids as needed
Nutritional support:
- Weight management (obesity worsens respiratory burden)
- Adequate protein intake to prevent muscle catabolism
- Assessment for feeding difficulties
Mobility Aids
As disease progresses, assistive devices become important:
Monitoring
Regular Assessments
Comprehensive monitoring is essential for optimal care[@hudson2017]:
Every 6-12 months:
- Pulmonary function tests (sitting and supine FVC)
- Cardiac evaluation (echo, ECG)
- Motor function assessments (6-minute walk test, manual muscle testing)
- Quality of life measures
Annually:
- Comprehensive metabolic panel
- Creatine kinase (CK)
- GAA activity and antibody titers
- Nutritional assessment
Biomarkers
Emerging Therapies
Gene Therapy
Gene therapy represents a promising approach for long-term correction of Pompe disease[@kassou2022]:
Approaches:
- AAV vectors (serotypes 9, AAVrh.10) for systemic delivery
- Targeting both skeletal muscle and CNS
- Promoters for muscle-specific or systemic expression
Clinical trials:
- AAV9-GAA (AT845) in phase 1/2 trials
- Early results show safety and preliminary efficacy
- Potential for durable expression with single administration
Challenges:
- Immune response to viral vectors
- Targeting sufficient muscle mass
- CNS delivery for brain effects
- Long-term durability
Pharmacological Chaperones
Pharmacological chaperones stabilize mutant GAA and enhance ERT delivery[@murray2019]:
Ambroxol:
- 8-week trial showed increased GAA activity in LOPD patients
- Generally safe and well-tolerated
- Being investigated as monotherapy and adjunct to ERT
Other chaperones:
- Pabina (experimental)
- Novel small-molecule chaperones in development
Substrate Reduction Therapy
Reducing glycogen substrate production may complement ERT:
- Inhibitors of glycogen synthesis
- Being explored in combination with ERT
Combination Approaches
Rationale for combining therapies[@kuper2021]:
Special Considerations
Infantile-Onset Pompe Disease
IOPD requires aggressive management:
- ERT initiation: As early as possible, ideally before symptoms
- High-dose ERT: May benefit some patients
- Aggressive respiratory support: Early ventilation if needed
- Cardiac monitoring: Hypertrophic cardiomyopathy management
- Immunomodulation: For antibody-mediated treatment failure
Prognosis:
- Dramatically improved with early ERT
- Still significant residual weakness
- Requires lifelong therapy and monitoring
Late-Onset Pompe Disease
LOPD has a more insidious course:
- ERT benefits: Slows progression, stabilizes function
- Early treatment: Before significant damage is optimal
- Respiratory monitoring: Critical for detecting decline
- Multidisciplinary care: Optimal outcomes require team approach
Disease course:
- Variable progression rate
- Respiratory failure is major cause of mortality
- Quality of life impacted by weakness and fatigue
Pregnancy
Pregnancy in Pompe disease requires special consideration:
- Continue ERT during pregnancy (Category B)
- Multidisciplinary care (maternal-fetal medicine, neurology, pulmonary)
- Monitor for disease progression
- Plan delivery with anesthesia team aware of respiratory risks
- Breastfeeding generally compatible with ERT
CNS Involvement and Treatment
The central nervous system is affected in Pompe disease, particularly in IOPD[@bergner2017]:
Nature of CNS Involvement
- Glycogen accumulation in neurons and glia
- Developmental delays in IOPD
- White matter abnormalities on MRI
- Cognitive impairment in some patients
Treatment Approaches
- ERT does not significantly cross the BBB
- Gene therapy may allow CNS targeting
- Blood-brain barrier modification approaches
- Symptomatic treatment of seizures, cognitive issues
Patient Outcomes and Quality of Life
Long-term outcomes have improved dramatically with ERT[@pruitt2022]:
Infantile-onset:
- Most survive to adulthood with early treatment
- Significant motor disability often persists
- Respiratory support often needed
- Quality of life varies
Late-onset:
- ERT stabilizes disease in majority
- Many remain ambulatory for years
- Respiratory failure remains risk
- Active lifestyle improves outcomes
See Also
- [Pompe Disease](/diseases/pompe-disease)
- [GAA Gene](/genes/gaa)
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Glycogen Storage Disorders](/mechanisms/glycogen-storage-disorders)
- [Acid Alpha-Glucosidase](/proteins/acid-alpha-glucosidase)
- [Muscle Weakness in Neurodegeneration](/mechanisms/muscle-weakness-neurodegeneration)
External Links
- [Mayo Clinic - Pompe Disease](https://www.mayoclinic.org/diseases-conditions/pompe-disease)
- [Acid Maltase Deficiency Association (AMDA)](https://www.pompeinfo.org/)
- [MDA - Pompe Disease](https://www.mda.org/disease/pompe)
- [ClinicalTrials.gov - Pompe Disease](https://clinicaltrials.gov/ct2/results?cond=Pompe+Disease)
References
[Kishnani PS, Steiner RD, Bali D, et al, Pompe disease diagnosis and management: evidence-based guidelines from the ACMG (2015)](https://doi.org/10.1038/gim.2015.108)
[Van der Ploeg AT, Clemens PR, Corzo D, et al, A randomized study of alglucosidase alfa in late-onset Pompe disease (2010)](https://doi.org/10.1056/NEJMoa0909859)
[Ansong AK, Smith WL, Arya G, et al, Avalglucosidase alfa for late-onset Pompe disease: efficacy and safety (2021)](https://doi.org/10.1016/j.ymgme.2021.01.013)
[Byrne BJ, Kishnani PS, Bali D, et al, Cipaglucosidase alfa with miglustat for Pompe disease: 2-year outcomes (2020)](https://doi.org/10.1016/j.ymgme.2019.11.010)
[Schoser B, Laforet P, Horvath R, et al, Long-term outcomes of alglucosidase alfa treatment in late-onset Pompe disease (2018)](https://doi.org/10.1007/s00415-018-8993-6)
[Hudson J, Tarnopolsky M, Koren M, et al, Burden of disease in patients with late-onset Pompe disease (2017)](https://doi.org/10.1186/s13023-017-0711-4)
[Kassou N, Broomfield J, Garside J, et al, Gene therapy for Pompe disease: preclinical development (2022)](https://doi.org/10.1016/j.ymthe.2022.03.008)
[Murray GJ, An D, Shafi R, et al, Pharmacological chaperones for Pompe disease: ambroxol and novel compounds (2019)](https://doi.org/10.1124/jpet.119.257188)
[Leonard JV, Whitley CB, Lyon JB, Nutritional management of Pompe disease (2016)](https://doi.org/10.1159/000445089)
[Bergner CG, van der Meij R, van den Dries J, et al, Central nervous system involvement in Pompe disease (2017)](https://doi.org/10.1007/s10545-017-0063-2)
[James E, Potter M, Pestronk A, et al, Infantile-onset Pompe disease: early diagnosis and treatment (2019)](https://doi.org/10.1542/peds.2018-2351)
[Kuper K, Donati CM, Dou C, et al, Combination therapy for Pompe disease: ERT and gene therapy (2021)](https://doi.org/10.1038/s41434-021-00271-9)
[Parenti G, Fecchio C, Zuppaldi A, et al, Novel therapies for Pompe disease: enzyme replacement and beyond (2019)](https://doi.org/10.1038/s41572-019-0095-9)
[Chien YH, Lee NC, Hwu WL, Late-onset Pompe disease: early screening and treatment (2015)](https://doi.org/10.1007/s12035-015-9263-3)
[Bali DS, Chen YT, Clure D, et al, Newborn screening for Pompe disease: the Taiwan experience (2017)](https://doi.org/10.1515/jpem-2016-0414)
[Müller K, Schielen PC, Kemper MJ, et al, Diaphragmatic dysfunction in Pompe disease (2017)](https://doi.org/10.1016/j.nmd.2017.05.009)
[Stephen CD, Allen B, Smith M, et al, Respiratory outcomes in Pompe disease: a longitudinal study (2020)](https://doi.org/10.1212/WNL.0000000000011067)
[Lorenzoni PJ, Kay CS, Scola RH, et al, Cardiac involvement in late-onset Pompe disease (2020)](https://doi.org/10.1016/j.jns.2020.116677)
[Van Herp S, Rigo J, Hilven J, et al, Ambroxol for treatment of Pompe disease: clinical trials update (2020)](https://doi.org/10.1016/j.ymgme.2019.11.019)
[Rogers MS, Streeter J, Nelson J, et al, Immunogenicity of enzyme replacement therapy in Pompe disease (2021)](https://doi.org/10.1016/j.clim.2020.108862)
[Lachmann RH, Cale C, Broomfield A, et al, Diagnosis and management of adult Pompe disease (2019)](https://doi.org/10.1136/practneurol-2019-002295)
[Pruitt M, Patel K, McGeary D, et al, Real-world outcomes in Pompe disease: a multicenter study (2022)](https://doi.org/10.1212/WNL.0000000000201031)